MammaPrint Genomic Test Helps Early Stage Cancer Patients Safely Avoid Chemo, Agendia’s CMO Says

MammaPrint Genomic Test Helps Early Stage Cancer Patients Safely Avoid Chemo, Agendia’s CMO Says
A genomic test, evaluated in several clinical trials and approved for use in the U.S. and Europe, can effectively tell early stage breast cancer patients what is their risk of cancer returning. The test, called MammaPrint 70-gene Breast Cancer recurrence assay, was developed by Agendia to give patients’ unambiguous low- and high-risk results. The test analyzes the activity of certain genes in early stage breast cancer and eliminates the uncertainty of other tests. Moreover, it can help clinicians in deciding whether chemotherapy, or other types of treatments aiming to reduce risk after surgery, are required. A prospective, randomized trial — the MINDACT Phase 3 clinical trial — was set up to investigate this exactly. In this study (NCT00433589), conducted in several European countries, researchers investigated MammaPrint 70-gene test's clinical utility as an additional approach to the standard criteria in selecting patients for adjuvant chemotherapy. The trial enrolled 6,693 women with early stage breast cancer and researchers used the 70-gene signature to determine their genomic risk and a modified version of Adjuvant! Online to determine their clinical risk. The latter is a platform that uses clinical data — patient age, tumor size, etc. — to estimate the risk of cancer recurrence. Trial results showed that while the clinical data categorized approximately 23 percent of women as hi
Subscribe or to access all post and page content.